Department of Pharmacology & Chemical Biology at the University of Pittsburgh
Julie Eiseman, PhD
Professor

Email:
jle9@pitt.edu

Education

BS (Chemistry), University of Michigan, Ann Arbor, MI, 1969
MS (Pharmacology), Michigan State University, East Lansing, MI, 1971
PhD (Pharmacology), Cornell University Medical College, New York, NY, 1980



Research Areas
Protein Kinases & Phosphatases
Cancer Pharmacology
Photo of Julie Eiseman, PhD





Important Publications
Eiseman J, J Lan, J Guo, E Joseph and Vucenik I.  Pharmacokinetics and tissue distribution of inositol hexaphosphate in C.B17 SCID mice bearing human breast cancer xenografts.  Metabolism 60:1465-1474, 2011.
Beumer JH, JL Eiseman, J Gilbert, JL Holleran, A Yellow-Duke, D Clausen, D D'Argenio, M Ames P Hershberger, RA Parise, L Bai, JA Covey and ML Egorin.  Plasma pharmacokinetics and oral bioavailabiity of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU) in mice.  Cancer Chemother Pharmacol 67:421-430, 2011.
Zamboni WC, Eiseman JL, S Strychor, PM Rice, E Joseph, BA Zamboni, MK Donnelly, J Shurer, RA Parise, ME Tonda, NY Yu and PH Basse.  Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.  J Liposome Res 21:70-80, 2011.
Clausen DM, J Guo, RA Parise, JH Beumer, MJ Egorin, JS Lazo, EV Prochownik and JL EisemanIn vitro cytotoxicity and in vivo efficacy, pharmacokinetics and metabolism of 10074-G5:  A novel small-molecule inhibitor of C-Myc/Max dimerization.  J Pharmacol Exp Ther 335:715-727, 2010.
Holleran JL, RA Parise, AE Yellow-Duke, MJ Egorin, JL Eiseman, JM Covey and JH Beumer.  Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.  J Pharm Biomed Anal 52:714-720, 2010.
Bai L, J Guo, FA Bontempo and JL Eiseman.  The relationship of phthalocyanine 4 (Pc 4) concentrations measured non-invasively to outcome of Pc 4 photodynamic therapy in mice.  Photochemistry and Photobiology 85:1011-1019, 2009.
Guo P, RA Parise, E Joseph, MJ Egorin, EK Prochownik and JL Eiseman.  Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.  Cancer Chemother Pharmacol 63:615-625, 2009.
Beumer JH, JL Eiseman, RA Parise, JM Covey and MJ Egorin.  Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.  Clin Cancer Res 14:3529-3535, 2008.
Eiseman JL, L Bai, W-H Jung, J Moura-Letts, BW Day and DP Curran.  Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts.  J Med Chem 51:6650-6653, 2008.




Back to Top